Hobbsthyssen5170

BACKGROUND There is currently no standardized and reproducible injection technique to address facial aging at all anatomical levels. OBJECTIVE The Sebban Technique One-point (STOP) Facial Aging Method™ for hyaluronic acid (HA) fillers aims to provide predictive results using a single point of entry. METHODS STOP combines two complementary techniques Deep One-point (DOP) and Superficial One-point (SOP). DOP targets the deep plane to restructure the facial architecture, while SOP targets the superficial and deeper hypodermic planes to add volume and provide optimal tissue hydration. The injection procedure involves one DOP phase and two SOP phases using an HA filler appropriate for the treatment indication and injection depth. STOP has been investigated in a retrospective, open-label observational case series. Cilofexor cost RESULTS Data from 10 women, aged 41 to 59 years, with varying stages of facial aging were retrospectively examined. Eight had received DOP with bolus injections of a cohesive HA filler and nine had received SOP using an HA filler with good elasticity to target the deep or superficial hypodermis. The mean total volume of HA filler injected (all HA fillers combined) was 5.46mL (range 4.0-7.0mL) for the whole face. Physician and patient satisfaction with the treatment was high and all subjects stated that they would recommend the treatment to their friends. The STOP protocol was well-tolerated and no complications were observed during the DOP or SOP phases. CONCLUSIONS STOP is a reproducible and safe technique for global facial rejuvenation with a single cannular point of entry.WNT10A plays a role in the proper proliferation and differentiation of ectodermal structures. Mutations in this gene can be responsible for a highly phenotypically variable range of disorders termed ectodermal dysplasias. Here, we describe the case of a five-year-old male patient who is mosaic for Turner syndrome (45,X [90%]/46,X isodicentric Y [10%]) and who presented to dermatology with anhidrosis, conical-shaped teeth, and a slowed rate of hair growth with genetic testing subsequently revealing a likely pathogenic heterozygous variant in WNT10A (c.682T>A; p.Phe228Ile). Future investigation into the WNT10A pathway, which is regulated downstream by β-catenin, might allow topical therapeutics to be developed that promote normal ectodermal growth and differentiation. Current management for this patient includes precautions taken to prevent overheating and heat stroke and close dermatological and dental monitoring.Isotretinoin has unmatched efficacy in the treatment of acne. However, because isotretinoin is a teratogen that can cause profound birth defects, the iPLEDGE program regulates the drug's distribution in the United States. To minimize fetal exposure to isotretinoin, the program requires that female patients capable of becoming pregnant use two forms of contraception or commit to abstinence while using this therapy. This manuscript argues that iPLEDGE should be revised to remove abstinence as an acceptable contraceptive option in the face of evidence that disputes its efficacy. All patients, regardless of reported sexual activity, should be required to use data-proven contraception. Potential benefits of the proposed change (iPLEDGE-R) include reducing the number of isotretinoin pregnancies, increasing patient privacy protection, and standardizing patient care. Further investigation needs to guide additional strategies to achieve the program's public health goal; however, the ethical and pragmatic advantages of iPLEDGE-R merit consideration.OBJECTIVE Oral health and mucocutaneous inflammation might play an important role in the etiopathogenesis of many skin diseases, especially those that also involve the oral mucosa. This review examines the relationship between skin conditions and various oral health metrics to better understand how oral diseases, especially periodontitis, might influence the development or prognosis of several conditions, including aphthous stomatitis, atopic dermatitis, lichen planus, pemphigus, pemphigoid, and psoriasis. METHODS Using the PubMed search engine between Summer 2017 and Summer 2018, searches were performed for oral health OR oral hygiene AND psoriasis, eczema, dermatitis, hidradenitis suppurativa, acne inversa, pyoderma gangrenosum, Sweet's syndrome, neutrophilic dermatosis, subcorneal pustular dermatosis, hives, urticaria, cutaneous lupus, pemphigoid, pemphigus, or lichen planus OR aphthous stomatitis. The abstract of articles written in English were reviewed by the investigators and selected for inclusion if tly being reported in dermatology, spurring collaboration between multiple specialists and dermatologists. This review emphasizes a need for closer collaboration between dermatologists and dentists to treat several common skin diseases.Desmoplastic trichilemmoma is a rare histological variant of a benign tumor of the pilosebaceous hair follicle that often clinically appears as similar in appearance to other cutaneous lesions. Here, an 81-year-old male patient with desmoplastic trichilemmoma found on the left zygoma is presented. During the dermatoscopic evaluation of the neoplasm, crown vessels with radial distribution in the periphery were displayed. Histopathologic evaluation revealed peripheral palisading lobules of tumor cells surrounded by sclerotic hyalinized stroma displacing the vessels of the tumor. This case highlights the value of using dermoscopy for improving the clinical diagnosis of desmoplastic trichilemmoma. These findings highlight a need to further investigate the diagnosis of desmoplastic trichilemmoma when crown vessels are displayed during the clinical evaluation.Pembrolizumab, an anti-programmed cell death protein 1 (PD-1) antibody, has demonstrated efficacy in treating metastatic melanoma. However, a handful of case reports have been published reporting autoimmune phenomena weeks after administration of the first dose of this immunomodulator. Although immunotherapy complications are not well known among dermatologists, they should be cognizant of this association between anti-programmed cell death protein 1 immunotherapy and autoimmune symptomology, since pembrolizumab has become a common therapy for metastatic melanoma. Here, the author presents a case of a patient with metastatic melanoma and a family history of autoimmune disease who presented with myositis in the weeks after receiving pembrolizumab.